Floatz logo

Inno-206

Sorafenib

Sun Yat-sen UniversityPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Sorafenib cohort.

Asset / SponsorPhaseRating
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 4BBB
Ethiodized Oil
Sun Yat-sen University
Phase 3B
Theprubicin
Sun Yat-sen University
Phase 3B
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3B
Toripalimab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3B
Gefetinib
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
D

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →